InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,477.90
(
0.16%
)
US TECH 100
19,199.60
(
-0.08%
)
Dow Jones
39,127.80
(
0.04%
)
Brent Oil
84.83
(
0.43%
)
Bitcoin
61,177.52
(
0.60%
)

Replies to post #214387 on Biotech Values

Replies to #214387 on Biotech Values

DewDiligence

10/18/17 11:27 AM

#214388 RE: CT #214387

...risk...related to getting the correct diagnosis for inclusion in these studies?

As you probably know, RVNC changed the protocol of the plantar facsiitis trial early on, essentially starting from scratch. Getting the diagnosis right may have been part of the problem addressed by the changes.